Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP13 | P45452 | 10/20 | 0.57 |
| ▸ | MMP2 | P08253 | 6/20 | 0.57 |
| ▸ | MMP14 | P50281 | 4/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.56 |
| ▸ | HPGD | P15428 | 3/20 | 0.56 |
| ▸ | RAB9A | P51151 | 3/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.56 |
| ▸ | NPC1 | O15118 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | GLA | P06280 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | ATM | Q13315 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30216943 | 1.00 | MMP13 (0.57) | MMP13MMP2MMP14KDM4EALDH1A1 | |
| SCHEMBL16306719 | 0.81 | MMP13 (0.58) | MMP13MMP2MMP14KDM4EALDH1A1 | |
| SCHEMBL31424468 | 0.81 | MMP13 (0.55) | MMP13MMP2MMP14KDM4EALDH1A1 | |
| SCHEMBL31424332 | 0.81 | MMP13 (0.55) | MMP13MMP2MMP14KDM4EALDH1A1 | |
| SCHEMBL30570851 | 0.79 | MAPK14 (0.39) | RAB9ANPC1KMT2AALOX15 | |
| SCHEMBL31229827 | 0.78 | ALDH1A1 (0.43) | KDM4EALDH1A1HPGDRAB9ASMN1; SMN2 | |
| SCHEMBL31413485 | 0.75 | PIK3CD (0.40) | KDM4EALDH1A1RAB9ASMN1; SMN2NPC1 | |
| SCHEMBL27151053 | 0.75 | PIK3CD (0.40) | KDM4EALDH1A1RAB9ASMN1; SMN2NPC1 | |
| SCHEMBL419130 | 0.75 | MMP13 (0.77) | MMP13MMP2MMP14KDM4EALDH1A1 | |
| SCHEMBL17109184 | 0.75 | KDM4E (0.52) | MMP13MMP2MMP14KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12617783-B2 | Heterocyclic GLP-1R agonists | BIOMEA FUSION, INC. (US) | 2026-05-05 | — | — | US | disclosed |
| US-20250304572-A1 | HETEROCYCLIC GLP-1R AGONISTS | BIOMEA FUSION, INC. | 2025-10-02 | — | — | US | disclosed |
| WO-2025119206-A1 | GLP-1 RECEPTOR TARGETING COMPOUNDS AND USES THEREOF | FORTVITA BIOLOGICS INC. (KY) | 2025-06-12 | — | — | WO | disclosed |
| EP-4097099-B9 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO INC (US) | 2025-04-30 | — | — | EP | disclosed |
| CN-119431365-A | Phenyl heterocyclic derivative-containing regulator and preparation method and application thereof | 江苏豪森药业集团有限公司 | 2025-02-14 | — | — | CN | disclosed |
| US-20240366639-A1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO INC (US) | 2024-11-07 | — | — | US | disclosed |
| EP-4458834-A2 | HETEROCYCLIC GLP-1 AGONISTS | Gasherbrum Bio, Inc. (US) | 2024-11-06 | — | — | EP | disclosed |
| US-12037339-B2 | Substituted imidazoles as GLP-1 receptor agonists | ECCOGENE INC. (US) | 2024-07-16 | — | — | US | disclosed |
| US-12037339-B2 | Substituted imidazoles as GLP-1 receptor agonists | ECCOGENE INC. (US) | 2024-07-16 | — | — | US | disclosed |
| EP-4097099-B1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO INC (US) | 2024-06-26 | — | — | EP | disclosed |
| US-11584751-B1 | Substituted imidazoles as GLP-1 receptor agonists | ECCOGENE (SHANGHAI) CO., LTD. (CN) | 2023-02-21 | — | — | US | disclosed |
| WO-2023016546-A1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO, INC. (US) | 2023-02-16 | — | — | WO | disclosed |
| WO-2023016546-A1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO, INC. (US) | 2023-02-16 | — | — | WO | disclosed |
| US-20230051320-A1 | TETRAHYDROPYRAZOLO-PYRAZINYL-DIHYDROIMIDAZOLONE OR TETRAHYDROPYRAZOLO-PYRIDINYL-DIHYDROIMIDAZOLONE COMPOUNDS AND METHODS OF USING SAME | ECCOGENE INC. | 2023-02-16 | — | — | US | disclosed |
| CN-115698003-A | Heterocyclic GLP-1 agonists | 加舒布鲁姆生物公司 | 2023-02-03 | — | — | CN | disclosed |
| EP-4097099-A1 | HETEROCYCLIC GLP-1 AGONISTS | Gasherbrum Bio, Inc. (US) | 2022-12-07 | — | — | EP | disclosed |
| US-11492365-B2 | Heterocyclic GLP-1 agonists | GASHERBRUM BIO, INC. (US) | 2022-11-08 | — | — | US | disclosed |
| US-20220213130-A1 | HETEROCYCLIC GLP-1 AGONISTS | SHANGHAI SHOUTI BIOTECHNOLOGY CO., LTD. (CN) | 2022-07-07 | — | — | US | disclosed |
| US-20220213130-A1 | HETEROCYCLIC GLP-1 AGONISTS | SHANGHAI SHOUTI BIOTECHNOLOGY CO., LTD. (CN) | 2022-07-07 | — | — | US | disclosed |
| WO-2021155841-A1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO, INC. (US) | 2021-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250304572-A1 | HETEROCYCLIC GLP-1R AGONISTS | GLP1R, GPR119, GIPR | MMP13 2784/4885MMP2 2640/4885MMP14 4289/4885 |
| US-20240366639-A1 | HETEROCYCLIC GLP-1 AGONISTS | GLP1R, GIPR, GCGR | MMP13 3895/4885MMP2 3565/4885MMP14 4546/4885 |
| US-20220213130-A1 | HETEROCYCLIC GLP-1 AGONISTS | GLP1R, GIPR, GCGR | MMP13 3826/4885MMP2 3387/4885MMP14 4693/4885 |
| US-11584751-B1 | Substituted imidazoles as GLP-1 receptor agonists | GLP1R, GIPR, SLC5A1 | MMP13 2948/4885MMP2 3230/4885MMP14 3502/4885 |
| US-20230051320-A1 | TETRAHYDROPYRAZOLO-PYRAZINYL-DIHYDROIMIDAZOLONE OR TETRAHYDROPYRAZOLO-PYRIDINYL-DIHYDROIMIDAZOLONE COMPOUNDS AND METHODS OF USING SAME | GLP1R, SLC5A1, GIPR | MMP13 3337/4885MMP2 3313/4885MMP14 2463/4885 |
| US-12617783-B2 | Heterocyclic GLP-1R agonists | GLP1R, GIPR, GPR119 | MMP13 3416/4885MMP2 2573/4885MMP14 4715/4885 |
| US-12037339-B2 | Substituted imidazoles as GLP-1 receptor agonists | GLP1R, GIPR, SLC5A1 | MMP13 2948/4885MMP2 3230/4885MMP14 3502/4885 |
| US-11492365-B2 | Heterocyclic GLP-1 agonists | GLP1R, GIPR, GCGR | MMP13 3826/4885MMP2 3387/4885MMP14 4693/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.